Evidence map›Paper›PMID 35182277›Full record

ArticleClinical and experimental nephrology2022

Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2.

Shigehisa Arikawa, Kazuhito Fukuoka, Keitaro Nakamoto, Rie Kunitomo, Yuki Matsuno, Teppei Shimazaki, Takeshi Saraya, Takahisa Kawakami, Mitsumasa Kishimoto, Yoshinori Komagata and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Therapeutic advances in COVID-19.Nature reviews. Nephrology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shigehisa ArikawaDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, PO 181-8611, Tokyo, Japan.
Kazuhito FukuokaDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, PO 181-8611, Tokyo, Japan. kfukuoka@ks.kyorin-u.ac.jp.ORCID http://orcid.org/0000-0003-3974-3082
Keitaro NakamotoDepartment of Respiratory Disease, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
Rie KunitomoDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, PO 181-8611, Tokyo, Japan.
Yuki MatsunoDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, PO 181-8611, Tokyo, Japan.
Teppei ShimazakiDepartment of General Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
Takeshi SarayaDepartment of Respiratory Disease, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
Takahisa KawakamiDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, PO 181-8611, Tokyo, Japan.
Mitsumasa KishimotoDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, PO 181-8611, Tokyo, Japan.
Yoshinori KomagataDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, PO 181-8611, Tokyo, Japan.
Daisuke KuraiDepartment of General Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
Haruyuki IshiDepartment of Respiratory Disease, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
Shinya KanameDepartment of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, PO 181-8611, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of patients with SARS-CoV-2 infection continues to increase, and it has become a global pandemic. Although there is an urgent need to establish an effective treatment, the medication available for dialysis patients has been limited. An antibody cocktail containing two SARS-CoV-2-neutrarizing antibodies, REGN-COV2 has been granted special approval for COVID-19 in Japan, since July 2021, and this intravenous preparation can be used for dialysis patients. At our hospital, we had 22 hemodialysis patients with COVID-19, and five of them were treated with REGN-COV2. On admission, four of the five patients had moderate disease (pneumonia but O

Indexed as

Antibodies, NeutralizingCOVID-19Antibodies, Monoclonal, HumanizedDrug CombinationsFemaleHumansMaleRenal DialysisSARS-CoV-2Antibodies, Monoclonal, HumanizedAntibodies, Neutralizingcasirivimab and imdevimab drug combinationDrug CombinationsCOVID-19End-stage kidney diseaseHemodialysisPneumoniaREG-COV2 (a neutralizing antibody cocktail)

Identifiers

PMID35182277
PMCPMC8856930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.